Phase 1 N=7 A Pilot Study of Robot-assisted Therapy for Post-stroke Forearm and Wrist Rehabilitation Training
Stroke
Primary: Motor Impairment of Wrist and Forearm — 23.57 Scores
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=56 Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions
Healthy
Primary: AUC0-∞ — 3960; 3400; 3350; 3420 ng*h/mL
Phase 1 N=16 Drug Drug Interaction of BI 201335 and Tenofovir
HIV Infections
Primary: Steady-state Pharmacokinetics of AUC0-24 of Tenofovir on Day 7 and on Day 15 — 2700; 3290 ng*h/mL
Phase 1 N=60 Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules
Hepatitis C
Primary: Area Under the Curve of the Analyte From Time 0 to the Last Quantifiable Data Point (AUC0-tz) — 17297.157; 17216.514 ng·h/mL
Phase 1 N=32 Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment
Hepatitis C
Primary: AUC0-∞ — 76500; 86900; 136000; 129000 ng*h/mL
Phase 1 N=15 Investigation of Food Effect and Gastric ph Increase on the Bioavailability of Faldapravir
Healthy
Primary: Faldaprevir: Area Under the Curve Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity) — 37900; 48200; 36000 [ng*h/mL] — p=0.3420
Phase 1 N=52 A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen
Metastatic Breast Cancer
Primary: Percentage of Participants With Adverse Events (AE), Serious Adverse Events (SAE), AEs With Grade >=3, and AEs Related To Treatment — 100; 100; 100; 100 percentage of…
Phase 1 N=8 Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD9291 in Volunteers
Healthy Volunteers
Primary: Percentage of Radioactive Dose of [14C] Radiolabelled AZD9291 Recovered in Urine, Faeces, and in Total. — 14.2; 67.8; 81.9 Percentage radioactive dose recovered
Phase 1 N=22 Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer
Stomach Cancer
Primary: Number of Participants With DLTs — 3 participants
Phase 1 N=21 Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors
Neoplasms
Primary: Number of Participants With an Adverse Event (AE), Serious Adverse Event (SAE), or Death — 3; 3; 4; 3 participants
Phase 1 N=29 Inactivation of Whole Blood With Mirasol
Focus of Study: Radiolabel Recovery and Survival of RBCs
Primary: Red Blood Cell (RBC) 24-Hour Recovery — 82.51; 91.70 % 24-hour RBC Recovery
Phase 1 N=24 Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets
Healthy
Primary: AUC0-∞ for Empagliflozin — 2780; 2870; 1110; 1070 nmol*h/L — p=0.0000
Phase 1 N=48 Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together
Healthy
Primary: Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Empagliflozin — 2810; 2580; 2760; 2570 nmol*h/L…
Phase 1 N=32 Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets
Healthy
Primary: AUC (0-tz) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) — 6260; 6360 ng*h/mL…
Phase 1 N=8 Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease
Sickle Cell Disease
Primary: Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide — 17.56; 32.95 μg/mL